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IMPAIRED IMMUNE RECONSTITUTION FOLLOWING ALLOGENEIC
HAEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN: MULTI-
VARIATE ANALYSIS OF CLINICAL RISK FACTORS
Kalwak, K.1, Gorczynska, E.1, Turkiewicz, D.1, Ussowicz, M.1,
Dyla, A.1, Chybicka, A.1 Department of Pediatric Hematology/Oncolo-
gy/BMT, Wroclaw Medical University, Wroclaw, Poland.
In children, only limited data on immune recovery post hema-
topoietic cell transplantation (HCT) are available. Our prospective
study included 191 patients who underwent allogeneic HCTs from
November 1996 to September 2004. The criterion of the quality of
reconstitution was the achievement of the ﬁfth percentile (p5) of
age-matched reference value for different lymphocyte subsets. The
analysis of the immune reconstitution after allogeneic HCT was
based on the logistic regression model, incl. a detailed multivariate
analysis. Different clinical factors affecting the immune recovery
were analyzed: type of transplant, source of stem cells, TBI, in-
vivo/in-vitro T cell depletion, CD34 cell content in the graft, acute
and chronic GvHD, CMV/BKV/ADV reactivation. The most im-
portant factors affecting the early recovery of lymphocytes were:
type of transplant and the use of in vivo or in vitro T cell depletion.
After HLA-identical sibling transplant the lymphocyte reconstitu-
tion was 4 and 7 times faster compared with the patients under-
going matched unrelated donor (MUD) or HLA-mismatched re-
lated donor transplants, respectively. Two groups of patients at risk
of developing EBV-LPD were identiﬁed: children undergoing
previous in vivo T cell depletion from the fourth month post
transplant and pts undergoing previous in vitro T cell depletion
from the third month post transplant onwards, respectively. The
faster late Th and B cell recovery after allogeneic BMT compared
to PBPCT may result from a younger age of BM donors (mainly
HLA-identical siblings). Therefore, in case of donor choice it is
optimal to collect BM or PBPC from the best youngest donor,
provided sufﬁcient CD34 cell number per kg recipient bw is
obtainable. Higher number of transplanted CD34 cells/kg recip-
ient bw favored faster T cell (incl. Th and Ts) recovery at 2–4 and
9–12 months post allogeneic HCT. In the course of early recovery,
it might result from the higher number of grafted T cells, incl.
mature memory T cells, whereas in the course of late reconstitu-
tion the second wave of T cell recovery, containing thymic emi-
grants began to dominate, which might be due to higher number of
grafted CD34 cells. The most important factor impairing the late
recovery of B and T cells (incl. Ts and naive Th cells) remained the
occurrence of extensive cGvHD. Therefore, the most effective way
to improve long-term immune recovery remains an optimal GvHD
prophylaxis decreasing the risk of extensive cGvHD.
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TRANSPLANT CONDITIONS DETERMINE THE KINETICS AND FRE-
QUENCY OF HOMEOSTATICALLY EXPANDING MEMORY CD8 T CELLS
IN SYNGENEIC HCT RECIPIENTS
Roskos, M.1, Levy, R.B.1 University of Miami Miller School of Medicine,
Miami, FL.
We are interested in studying the contributions of memory CD8
T cells to immune reconstitution following ablative and non-
ablative conditioning and hematopoietic cell transplantation
(HCT). Our studies have focused on memory CD8 T cells (TM)
for several reasons. First, TM are highly represented in the marrow
compartment and are thus frequently administered as part of the
progenitor cell inoculum. Moreover, due to their enhanced radio-
resistance, populations of host CD8 TM are also likely to survive
preferentially following conditioning. Finally, CD8 TM cells may
have greater therapeutic beneﬁts compared to naı¨ve cells; for ex-
ample, TM can respond more rapidly and more intensely to lower
concentrations of antigen. To investigate the homeostatic expan-
sion and persistence of donor CD8 TM during and after immune
reconstitution, a homogeneous TCR-transgenic (tg) TM popula-
tion was generated in vitro and infused in a syngeneic murine HCT
model. Brieﬂy, the in vitro-derived TM population was generated
from the spleen cells of OT.I-RAG1/ tg mice cultured for 3 days
with rmIL-2 and OVA peptide, harvested, and re-cultured for 2–4
days with rmIL-15. The resultant OT.I cells (CD44hi/ Ly6C/
CD62L/ CD25lo) exhibited a central memory phenotype. Vary-
ing numbers of OT.I TM, together with T cell-depleted B6 bone
marrow (2  106), were transplanted into ablatively conditioned
syngeneic recipients. Homeostatic expansion was assessed by
CD8, V5, V
2 cell numbers in recipient spleens and bone
marrow 3 to 42 days post-HCT. Table 1 summarizes the homeo-
static expansion of OT.I TM in recipient spleens following trans-
plant (Table 1). Similar ﬁndings were observed in the recipient
marrow compartment. Notably, OT-I TM co-transplanted after
reduced intensity conditioning shifted the kinetics of expansion to
an earlier time post-transplant and resulted in lower overall ho-
meostatic numbers. In total, these results demonstrate that the
kinetics, the maximal numbers of CD8 TM, and their ultimate
homeostatic numbers depend on both the number of CD8 TM
infused and the intensity of recipient conditioning. Currently,
experiments are underway to investigate the effect of delayed
infusions of OT.I TM on homeostatic expansion. Thus, the
number of CD8 TM infused and the level of conditioning
administered are likely important when engineering new strat-
egies designed to enhance immune function post-transplant,
including both immediate anti-tumor immunity and long-term
anti-viral protection.
Homeostatic Expansion of OT.I TM in 9.0Gy Conditioned HCT
Recipients
OT.I TM
Infused
(106)
Period of
Expansion (Days)
Maximum
Number of
OT.I TM (10
6)
Homeostatic
Number of
OT.I TM
(106)
0.1 7 0.7 0.7
1.5 14 2.3 2.3
10
7 (followed by 7 days
of contraction) 15 4.8
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RAPID IN VIVO ACQUISITION OF EFFECTOR Tc1 PHENOTYPE PRIOR TO
MYELOID ENGRAFTMENT PREDICTS OPPORTUNISTIC INFECTIONS IN
UNRELATED CORD BLOOD TRANSPLANT RECIPIENTS
Szabolcs, P.1, Lee, Y.A.1, Reese, M.1, Chao, N.2, Kurtzberg, J.1 1. Duke
University Medical Center, Pediatric Blood and Marrow Transplant
Program, Durham, NC; 2. Duke University, Department of Medicine,
Cellular Therapy, Durham, NC.
The major cause of morbidity and mortality after unrelated cord
blood transplantation (UCBT) is opportunistic infections (OI),
most occurring in the ﬁrst 100 days due to viral agents. Despite
	5  106/kg of T cells in UCB grafts they are naive, lack expres-
sion of Th1/Tc1 cytokines, granzymes A, B, and perforin, prereq-
uisites for controlling viral pathogens. We postulated that follow-
ing transplant the infused T cells will undergo phenotypic
alterations induced by the lymphopenic environment and emerg-
ing de novo or latent viruses. These changes may identify those at
risk for OI even before virological/clinical diagnosis is evident.
Methods: 72 pediatric recipients of HLA-mismatched UCBT, and
evaluable for day100 infection rate, were studied prospectively as
soon as the WBC exceeded 300/l, at a median of day 18,
typically before myeloid engraftment and prior to the onset of
clinical infections. Unprocessed whole blood was stained in “Tru-
count” (B-D) tubes for absolute T cell and dendritic cell (DC1,
DC2) counts. T cells subsets were analyzed for expression of
homing and activation antigens by 4 color FACS from Ficolled
specimens. Intracellular staining identiﬁed cytotoxic effectors and
inducible cytokine secretion along with rates of in vivo prolifera-
tion and apoptosis. Signiﬁcant variables between OI  and OI
groups (P .05) were identiﬁed by 2-tailed Student’s t-test and are
presented in Table 1. Results: 41 of 72 patients developed OI
within day 100 at a median of D35, (39 viral cases, 1 case of
Legionella and Candida). While only 3/31 non-OI patients died
(relapse), 18/39 from the OI group died at a median of 82 days
post UCBT, P .001. Median f/up of survivors is 28 17 months.
Poster Session I
83BB&MT
Age, malignancy, and cell dose had no impact on OI. The median
values for major leukocytes were; WBC: 0.7  10e3/l, T cells:
63/l, NK cells: 47/l, B cells: 0/l, CD4T cells: 42/l,
%CD4 T cells: 66%. Both the OI and OI group had com-
parable WBC, CD3, CD4 T cells, NK lymphocytes, or DC1,
DC2 subsets. Strikingly, 44% of circulating T cells were in cell
cycle (KI-67) and 10% were entering apoptosis (activated
Caspase-3), regardless of OI status. Only 16% preserved the
CD45RA/CD62L phenotype of the infused graft. We con-
clude that in lymphopenic UCBT recipients even undetectable
viral infections may induce T cell maturation towards effector
CD8 Tc1 cells as soon as 2–3 weeks after UCBT allowing early
identiﬁcation of those at risk for clinical OI (Table1).
Differences in Lymphocyte Reconstitution Between Those Who Will
Develop Opportunisitic Infections (OI) or Not
Variable
OI Median
Value
OI Median
Value P-Value
% CD8 T cells 39 28 .04
% CCR-5 T cells 85 56 .005
% CD8/CD57/CD28 6 2.8 .027
Abs
CD8/CD57/CD28 1.3 0.4 .017
% IFN T cells 35.1 12.2 .006
% CD4/IFN T cells 14 10 .017
% CD8/Perforin T cells 48 26 .019
MFI of BCL-2 in T cells 76 54 .036
Absolute values in microliter.
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FACTORS AFFECTING IMMUNOLOGIC RECOVERY AFTER NONMYELOA-
BLATIVE CONDITIONING
Baron, F.1, Piette, F.1, Maris, M.1, Storek, J.1, Metcalf, M.1,
White, K.1, Sandmaier, B.1, Maloney, D.1, Storer, B.1, Storb, R.1,
Boeckh, M.1 Fred Hutchinson Cancer Research Center, Seattle, WA.
Background/Methods: We investigated factors affecting im-
mune recovery after nonmyeloablative (NM) conditioning in 94
pts given PBSC from HLA-matched related (MRD, n  51) or
unrelated (URD, n  43) donors after 2 Gy TBI / ﬂudarabine.
Postgrafting immunosuppression (IS) consisted of mycophenolate
mofetil (MMF, given TID for 40 days followed by a 56 day taper
in URD recipients, and BID for 28 days in MRD recipients) and
cyclosporin. Univariate and multivariate analyses were performed
to determine factors affecting counts of CD4 T cells, naive CD4 T
cells, CD8 T cells, B cells, and frequency of CMV-speciﬁc CD4
T-helper cells (among CMV seropositive pts or CMV-seronega-
tive pts with CMV-seropositive donors; determined by lympho-
proliferation (CMV-CPM)) on days 30, 80, 180, and 365 after
HCT.Results: In multivariate analyses, URD recipients had lower
counts of CD4 T cells, naive CD4 T cells, CD8 T cells, and
CMV-CPM than MRD on day 30 after HCT. This delay in
CMV-speciﬁc immune reconstitution was accompanied by in-
creased frequency of CMV-reactivation (and increased use of pre-
emptive antiviral therapy [PET]) among CMV-seropositive pts or
CMV-seronegative pts with CMV sero-positive donors given
URD grafts (cumulative incidence [CI] 61%) compared with MRD
(33%) recipients the ﬁrst 100 days after HCT. This did not lead to
increased CMV disease among URD recipients (1 episode) com-
pared with MRD recipients (1 episode), demonstrating that PET
was similarly effective in preventing CMV diseases in both groups.
Higher donor age was associated with lower counts of naive CD4
T cells, suggesting that most naive CD4 T cells derived from
transplanted naive CD4 T cells rather than through neo-genera-
tion. As seen in pts given myeloablative conditioning, CMV-sero-
positive patients had higher levels of CD8 T cells after HCT.
Further, lower levels of T cells and CD34 cells in the grafts, as
well as acute GVHD, impaired immune recovery of naive CD4 T
cells and B-cells (Table 1). Conclusions: Despite similar NM
conditioning regimens, immunologic recovery was delayed among
URD recipients in comparison to MRD recipients, either because
of increased/extended postgrafting IS or the greater degrees of
antigenic disparities between donors and recipients. This resulted
in a higher incidence of CMV-infection and increased use of PET.
Other factors associated with immune recovery were donor age,
patient CMV-serostatus, number of CD34 and T cells in the graft,
as well as acute GVHD (Table 1).
Table 1. Multivariate Analyses of Factors Affecting Immune
Recovery After NM Conditioning
Cell Subset
Day
After HCT
Factor(s) Associated With
Lower Cell Subset Counts
CD4 T-cell 30 URD vs MRD (P  .06)
CD4 T-cell 80 URD vs MRD (P  .003);
High donor age
(P  .006)
CD4 T-cell 180 & 365 MRD vs URD (P  .035)
Naive CD4 T-cell 30 URD vs MRD (P < .001);
High donor age
(P  .001)
Naive CD4 T-cell 80 Low # of CD34 cells
transplanted (P  .006);
Grade II–IV acute
GVHD (P  .007)
Naive CD4 T-cell 180 & 365 High donor age
(P  .003); Pt CMV
seropositive (P  .03)
CD8 T-cell 30 URD vs MRD (P < .001)
CD8 T-cell 80 Pt CMV seronegative
(P  .018)
CD8 T-cell 180 & 365 Pt CMV seronegative
(P  .06)
B-cell 30 Low no. of CD34 cells
transplanted
(P  .022); Low # of
T-cells transplanted
(P  .039)
B-cell 80 Low no. of T-cells
transplanted
(P  .002); Grade II–IV
acute GVHD (P  .08)
B-cell 180 & 365 Grade II–IV acute GVHD
(P  .031)
CMV-
CPM† 30 URD vs MRD (P  .007)
CMV-
CPM† 80 URD vs MRD (P  .008);
Low no. of T-cells
transplanted (P  .02)
CMV-
CPM† 180 & 365 Low no. of T-cells
transplanted (P  .01)
Other factors assessed were pt age, prior chemotherapy or not,
day 28 T-cell chimerism, extensive chronic GVHD; contin-
uous linear variable; †analyses restricted to CMV seropositive
pt or donor.
240
SIGNIFICANCE OF LYMPHOCYTE CONTRIBUTION POST PROCESSING IN
CORD BLOOD TRANSPLANTATION
Wofford, J.D.1, Regan, D.M.1, Alonso, J.M.F.1, Creer, M.H.2 1. St.
Louis Cord Blood Bank at SSM Cardinal Glennon Children’s Hospital,
St. Louis, MO; 2. St. Louis University, St. Louis, MO.
In cord blood transplantation, engrafting cell populations include
hematopoietic stem/progenitor cells. Naive and antigen-speciﬁc T
and B cells mediate protective immune responses as well as graft-
versus-host reactions. Total Nucleated Cell Dose (TNC) has con-
sistently been shown to correlate with recipient outcome. A major
complication, including death, in post transplant recovery is infec-
tion. In this preliminary analysis, we attempt to determine the
signiﬁcance of the lymphocyte contribution with regard to infec-
tion control post cord blood infusion. The outcomes of 318 single
cord blood unit transplants have been evaluated. Recipients were
assigned to groups based on the percentage of lymphocytes post
processing. The overall mean was 30%. Group 1 consists of recip-
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